Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01337245 · ClinicalTrials.gov registry record · Phase 3
Emergency Treatment of Coral Snake Envenomation With Antivenom
A Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 5
- Study locations
NCT01337245: Completed Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom, sponsored by University of Arizona.
NCT01337245 is a Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom that has completed, run by University of Arizona. The registered enrollment target is 26 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01337245, a Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to see whether a new F(ab')2 antivenom will prevent injury and death from the bite of a coral snake. Funding Source - FDA OOPD.
Conditions Studied
Interventions
- DRUG Snake (Micrurus) North American immune F(ab')2 Equine
Study Locations (5)
Florida
- Florida Hospital Deland - DeLand
- Lee Memorial Hospital - Fort Myers
- St. Lucie Medical Center - Port Saint Lucie
- Tampa General Hospital - Tampa
Arizona
- Banner University Medical Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-11-11 |
| Phase | Phase 3 |
What the finished NCT01337245 record still lists
NCT01337245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Coral Snake Bite appearing as the primary indexed condition, and to 1 intervention - of which Snake (Micrurus) North American immune F(ab')2 Equine is the first listed.
NCT01337245 lists 5 locations in 2 states (Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT01337245 about?
NCT01337245 is a clinical study titled "Emergency Treatment of Coral Snake Envenomation With Antivenom". The purpose of this study is to see whether a new F(ab')2 antivenom will prevent injury and death from the bite of a coral snake. Funding Source - FDA OOPD.
What is the current status of trial NCT01337245?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2012-05. Estimated completion is 2016-11-11.
What conditions does trial NCT01337245 study?
This clinical trial studies the following conditions: Coral Snake Bite, Toxic Effect of Coral Snake Venom.
What interventions are being tested in trial NCT01337245?
The interventions under investigation include: Snake (Micrurus) North American immune F(ab')2 Equine (DRUG).
Who is sponsoring clinical trial NCT01337245?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01337245 being conducted?
This trial has 5 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01337245's enrollment target sits among peer trials
26 1937th of 2000 higher than 60 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia